|
JPS5991308A
(ja)
*
|
1982-11-16 |
1984-05-26 |
Kawasaki Heavy Ind Ltd |
平面の検出方法
|
|
US7098190B1
(en)
*
|
1999-01-27 |
2006-08-29 |
Coda Therapeutics Ltd. |
Formulations comprising antisense nucleotides to connexins
|
|
EP1197553A1
(en)
*
|
2000-10-12 |
2002-04-17 |
A3D GmbH, Antisense Design & Drug Development |
Antisense nucleic acid against alphaV integrin
|
|
US20050119211A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
|
|
CN1922320B
(zh)
*
|
2003-12-03 |
2013-04-24 |
科达治疗（新西兰）有限公司 |
靶向连接蛋白的反义化合物及其使用方法
|
|
US9408381B2
(en)
|
2004-12-21 |
2016-08-09 |
Musc Foundation For Research Development |
Alpha Connexin c-Terminal (ACT) peptides for use in transplant
|
|
EP1827480B1
(en)
*
|
2004-12-21 |
2016-11-09 |
MUSC Foundation For Research Development |
Compositions and methods for promoting wound healing and tissue regeneration
|
|
CN101573131B
(zh)
|
2005-02-03 |
2017-12-01 |
科达治疗有限公司 |
抗‑连接蛋白化合物及其治疗应用
|
|
US20090163432A1
(en)
*
|
2005-11-08 |
2009-06-25 |
Kansai Technology Licensing Organization Co., Ltd. |
Therapeutic Agent for Corneal Diseases
|
|
CN103301475B
(zh)
|
2005-12-28 |
2016-08-03 |
斯克里普斯研究所 |
药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
|
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
RU2542471C2
(ru)
|
2006-11-15 |
2015-02-20 |
Коуда Терапьютикс, Инк. |
Улучшенные способы и композиции для заживления ран
|
|
PL2101791T3
(pl)
*
|
2006-12-11 |
2015-04-30 |
Coda Therapeutics Inc |
Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia
|
|
AU2014204482B2
(en)
*
|
2006-12-11 |
2016-07-07 |
Coda Therapeutics, Inc. |
Anticonnexin polynucleotides as impaired wound healing compositions
|
|
US20110130345A1
(en)
*
|
2007-06-21 |
2011-06-02 |
Baerbel Rohrer |
Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration
|
|
CA2701845A1
(en)
|
2007-10-03 |
2009-04-09 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
|
CN102920996A
(zh)
*
|
2007-12-11 |
2013-02-13 |
科达治疗公司 |
受损伤口愈合的药物组合物
|
|
AU2008335717A1
(en)
|
2007-12-11 |
2009-06-18 |
Coda Therapeutics, Inc. |
Impaired wound healing compositions and treatments
|
|
AU2008343754A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polynucleotides for the treatment of surgical adhesions
|
|
JP2011507860A
(ja)
*
|
2007-12-21 |
2011-03-10 |
コーダ セラピューティクス， インコーポレイテッド |
異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
|
|
US20110243964A1
(en)
*
|
2007-12-21 |
2011-10-06 |
Bradford James Duft |
Treatment of orthopedic conditions
|
|
AU2008343840A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
|
|
EP2237795A2
(en)
*
|
2007-12-21 |
2010-10-13 |
Coda Therapeutics, Inc. |
Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
|
|
EP2234656A2
(en)
|
2007-12-21 |
2010-10-06 |
Coda Therapeutics, Inc. |
Improved medical devices
|
|
EP2252690A2
(en)
*
|
2007-12-21 |
2010-11-24 |
Coda Therapeutics, Inc. |
Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
|
|
EP2237796A2
(en)
*
|
2007-12-21 |
2010-10-13 |
Coda Therapeutics, Inc. |
Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
|
|
CA2710380A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
|
|
WO2009097077A2
(en)
*
|
2008-01-07 |
2009-08-06 |
Coda Therapeutics, Inc. |
Wound healing compositions and treatments
|
|
EP2342340A1
(en)
|
2008-09-22 |
2011-07-13 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
MY188457A
(en)
|
2008-10-03 |
2021-12-10 |
Opko Curna Llc |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
CA2745329C
(en)
|
2008-12-04 |
2022-07-12 |
Opko Curna, Llc |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
|
WO2010065671A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
|
KR20110091796A
(ko)
|
2008-12-04 |
2011-08-12 |
오피케이오 큐알엔에이, 엘엘씨 |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
US8669941B2
(en)
*
|
2009-01-05 |
2014-03-11 |
Nuance Communications, Inc. |
Method and apparatus for text entry
|
|
HUE026280T2
(en)
|
2009-02-12 |
2016-06-28 |
Curna Inc |
Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
|
|
MX2011009751A
(es)
|
2009-03-16 |
2011-09-29 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
|
|
US9708604B2
(en)
|
2009-03-17 |
2017-07-18 |
Curna, Inc. |
Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
|
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
|
EP2427554B1
(en)
|
2009-05-08 |
2016-11-16 |
CuRNA, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
|
|
KR101704988B1
(ko)
|
2009-05-28 |
2017-02-08 |
큐알엔에이, 인크. |
항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
|
|
ES2629339T3
(es)
|
2009-06-16 |
2017-08-08 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
|
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
|
KR101801407B1
(ko)
|
2009-07-24 |
2017-11-24 |
큐알엔에이, 인크. |
시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
|
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
|
US9044493B2
(en)
|
2009-08-11 |
2015-06-02 |
Curna, Inc. |
Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
|
|
CN102482670B
(zh)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
|
|
CN102482671B
(zh)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
|
|
NO2480669T3
(enExample)
|
2009-09-25 |
2018-04-07 |
|
|
|
CA2782366A1
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
|
US8921334B2
(en)
|
2009-12-29 |
2014-12-30 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
|
|
ES2585829T3
(es)
|
2009-12-29 |
2016-10-10 |
Curna, Inc. |
Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
|
|
CA2785727C
(en)
|
2009-12-31 |
2020-01-07 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
|
NO2524039T3
(enExample)
|
2010-01-11 |
2018-04-28 |
|
|
|
ES2671877T3
(es)
|
2010-01-25 |
2018-06-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
|
|
WO2011103528A2
(en)
|
2010-02-22 |
2011-08-25 |
Opko Curna Llc |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
|
CN102869777B
(zh)
|
2010-04-02 |
2018-11-02 |
库尔纳公司 |
通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
|
|
WO2011127337A2
(en)
|
2010-04-09 |
2011-10-13 |
Opko Curna Llc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
WO2011150005A2
(en)
|
2010-05-26 |
2011-12-01 |
Opko Curna Llc |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
|
DK2576784T3
(en)
|
2010-05-26 |
2018-02-26 |
Curna Inc |
TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
|
|
CN109112126B
(zh)
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
|
CN103068982B
(zh)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
|
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
|
US8987225B2
(en)
|
2010-11-23 |
2015-03-24 |
Curna, Inc. |
Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
|
|
WO2012170771A1
(en)
|
2011-06-09 |
2012-12-13 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
|
KR101991980B1
(ko)
|
2011-09-06 |
2019-06-21 |
큐알엔에이, 인크. |
소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
|
|
AU2013219799C1
(en)
|
2012-02-15 |
2017-12-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating and preventing diseases and disorders of the central nervous system
|
|
MX351881B
(es)
|
2012-03-01 |
2017-11-01 |
Firststring Res Inc |
Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
|
|
ES2694592T3
(es)
|
2012-03-15 |
2018-12-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
|
|
JP2015513905A
(ja)
|
2012-03-27 |
2015-05-18 |
コーダ セラピューティクス， インコーポレイテッド |
カドヘリン調節に基づく組成物および処置
|
|
US20140274872A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Coda Therapeutics, Inc. |
Compositions and treatments based on cadherin modulation
|
|
US20170166897A1
(en)
*
|
2013-03-11 |
2017-06-15 |
University Of North Carolina At Chapel Hill |
Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
|
|
US9156896B2
(en)
|
2013-03-15 |
2015-10-13 |
Coda Therapeutics, Inc. |
Wound healing compositions and treatments
|
|
WO2015085113A1
(en)
*
|
2013-12-04 |
2015-06-11 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
|
WO2015130840A2
(en)
*
|
2014-02-25 |
2015-09-03 |
Coda Therapeutics, Inc. |
Treatment of resistant lesions
|
|
CA2951721C
(en)
|
2014-06-12 |
2023-09-26 |
The Research Foundation For The State University Of New York |
Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
|
|
WO2016029191A2
(en)
|
2014-08-22 |
2016-02-25 |
Auckland Uniservices Limited |
Channel modulators
|
|
EP3188799B1
(en)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
|
AU2017224122B2
(en)
*
|
2016-02-26 |
2024-04-11 |
The Board Of Regents Of The University Of Texas System |
Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
|
|
JP7167059B2
(ja)
*
|
2017-04-19 |
2022-11-08 |
フィオ ファーマシューティカルズ コーポレーション |
核酸化合物の局所送達
|
|
CN111201247A
(zh)
|
2017-04-28 |
2020-05-26 |
奥克兰联合服务有限公司 |
治疗方法和新颖构建体
|
|
EP3685824A1
(en)
*
|
2019-01-25 |
2020-07-29 |
Breitenbronn-Consulting GbR |
Composition for administering and releasing oligonucleotides
|
|
US12138293B2
(en)
|
2020-10-22 |
2024-11-12 |
Xequel Bio, Inc. |
Peptide formulations and ophthalmic uses thereof
|
|
WO2023219655A1
(en)
*
|
2022-05-13 |
2023-11-16 |
University Of Utah Research Foundation |
Gja1-20k to limited cardiac arrhythmias
|
|
US12667586B2
(en)
|
2023-03-07 |
2026-06-30 |
Glaukos Corporation |
Treatments for ocular surface disorders
|